F8 and hemophilia B: Treatment of PWH involves FVIII or FIX replacement products; however, 25–50% of persons with hemophilia A and 1–3% with hemophilia B develop inhibitors (i.e., neutralizing antibodies) against FVIII or FIX, respectively, which can render these products ineffective2.